v3.26.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2026
Mar. 31, 2026
Current assets:    
Cash and cash equivalents $ 1,642,266 $ 1,419,232
Marketable securities 2,565,320 2,872,601
Litigation settlement receivable 0 770,235
Other current assets 147,957 105,316
Total current assets 4,355,543 5,167,384
Property and equipment, net 10,942 11,986
Operating lease right-of-use assets 77,317 80,416
Investments measured at fair value 504,914 407,985
Other assets 27,108 40,916
Total assets 4,975,824 5,708,687
Current liabilities:    
Accounts payable 11,304 18,002
Accrued expenses 187,870 205,823
Operating lease liabilities 13,778 11,147
Income tax payable 59,076 45,689
Other current liabilities 7,883 583
Total current liabilities 279,911 281,244
Operating lease liabilities, noncurrent 92,792 96,291
Income tax payable, noncurrent 0 38,670
Other liabilities 7,401 70
Total liabilities 380,104 416,275
Commitments and contingencies (Note 11)
Shareholders’ equity:    
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 723,687,406 and 720,352,386 shares issued and outstanding at September 30, 2026 and March 31, 2026, respectively 0 0
Additional paid-in capital 5,193,719 5,024,826
Accumulated deficit (1,164,473) (501,814)
Accumulated other comprehensive (loss) income (8,931) 4,358
Shareholders’ equity attributable to Roivant Sciences Ltd. 4,020,315 4,527,370
Noncontrolling interests 575,405 765,042
Total shareholders’ equity 4,595,720 5,292,412
Total liabilities and shareholders’ equity $ 4,975,824 $ 5,708,687